<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02579759</url>
  </required_header>
  <id_info>
    <org_study_id>CLN-PXT3003-02</org_study_id>
    <secondary_id>2015-002378-19</secondary_id>
    <nct_id>NCT02579759</nct_id>
  </id_info>
  <brief_title>Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)</brief_title>
  <acronym>PLEO-CMT</acronym>
  <official_title>International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharnext SA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharnext SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether PXT3003 is effective and safe in the
      treatment of Charcot-Marie-Tooth disease - Type 1 A (CMT1A). This double-blind study will
      assess in parallel groups 2 doses of PXT3003 compared to Placebo in CMT1A patients treated
      for 15 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PXT3003, is a fixed dose combination of (RS)-baclofen, naltrexone hydrochloride and
      D-sorbitol selected via a Systems Biology approach and developed by Pharnext, with the aim to
      lower toxic PMP22 gene over-expression in CMT1A. On September 18th 2017, the PXT3003 dose 2
      was prematurely discontinued, due to an unexpected investigational medicinal product quality
      event (failed month 18 stability testing). The independent data safety monitoring committee
      did not identify any safety concern on September 5th 2017. All patients randomised to dose 2
      were requested to undergo the end of study visit, and were offered to enter the extension
      study (CLN-PXT3003-03).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disability measured by the change in the Overall Neuropathy Limitation Scale (ONLS) score</measure>
    <time_frame>12 and 15 months of treatment</time_frame>
    <description>Analysis of Covariance on the summary mean of ONLS at 12 and 15 months adjusted for baseline ONLS values.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Responder rate to PXT3003 therapy defined as a patients improving on ONLS at end of treatment</measure>
    <time_frame>15 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm and leg sub-items of ONLS</measure>
    <time_frame>12 and 15 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Charcot-Marie-Tooth Neuropathy Score version 2 (CMTNS-v2), including its sub-items</measure>
    <time_frame>12 and 15 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nine-hole Peg Test (9-HPT) performed on non-dominant hand</measure>
    <time_frame>12 and 15 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantified Muscular Testing (QMT) by Hand grip and Foot dorsiflexion dynamometry (mean of both sides)</measure>
    <time_frame>12 and 15 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to walk 10 meters</measure>
    <time_frame>12 and 15 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compound Muscle Amplitude Potential (CMAP) in ulnar or median nerves (non-dominant side)</measure>
    <time_frame>12 and 15 months of treatment</time_frame>
    <description>mV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensory Nerve Potential Amplitude (SNAP) in radial nerve (non-dominant side)</measure>
    <time_frame>12 and 15 months of treatment</time_frame>
    <description>µV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nerve Conduction Velocity (non-dominant side)</measure>
    <time_frame>12 and 15 months of treatment</time_frame>
    <description>m/sec</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured by the EuroQol 5-Dimensional Health-related Quality of Life scale (EQ-5D-L)</measure>
    <time_frame>12 and 15 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual analog scale on self-assessment of the individualized main impairment in daily activities defined at baseline with the patient</measure>
    <time_frame>12 and 15 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of PXT3003: assessment of some AE incidence and of the change in physical examination, vital signs, clinical laboratory variables, and ECGs.</measure>
    <time_frame>15 months of treatment</time_frame>
    <description>Incidence of Treatment Emergent Adverse Events (TEAE), of related TEAE with moderate or severe intensity, AE leading to withdrawal of study drug, and Serious Adverse Events,</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">323</enrollment>
  <condition>Charcot-Marie-Tooth Disease Type 1A</condition>
  <arm_group>
    <arm_group_label>PXT3003 dose 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral solution, 5 ml b.i.d. (taken morning and evening with food) during 15 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PXT3003 dose 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral solution, 5 ml b.i.d. (taken morning and evening with food) during 15 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral solution, 5 ml b.i.d. (taken morning and evening with food) during 15 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PXT3003 dose 1</intervention_name>
    <description>Liquid oral solution, 5 ml twice a day, morning and evening with food</description>
    <arm_group_label>PXT3003 dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PXT3003 dose 2</intervention_name>
    <description>Liquid oral solution, 5 ml twice a day, morning and evening with food</description>
    <arm_group_label>PXT3003 dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Liquid oral solution, 5 ml twice a day, morning and evening with food</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged from 16 to 65 years;

          -  Patient with a proven genetic diagnosis of CMT1A;

          -  Mild-to-moderate severity assessed by Charcot-Marie-Tooth Neuropathy Score (version 2)
             with a score &gt;2 and ≤18;

          -  Muscle weakness in at least foot dorsiflexion;

          -  Motor nerve conduction of the ulnar nerve of at least 15 m/sec;

          -  Providing signed written informed consent to participate in the study and willing and
             able to comply with all study procedures and scheduled visits.

        Exclusion Criteria:

          -  Any other associated cause of peripheral neuropathy such as diabetes;

          -  Patient with another significant neurological disease or a concomitant major systemic
             disease;

          -  Clinically significant history of unstable medical illness since the last 30 days
             (unstable angina, cancer…) that may jeopardize the participation in the study;

          -  Significant hematologic disease, hepatitis or liver failure, renal failure;

          -  Limb surgery within six months before randomization or planned before trial
             completion;

          -  Clinically significant abnormalities on the pre-study laboratory evaluation, physical
             evaluation, electrocardiogram (ECG);

          -  Elevated ASAT/ALAT (&gt; 3 x ULN) and elevated serum creatinine levels (&gt; 1.25 x ULN);

          -  History of recent alcohol or drug abuse or non-adherence with treatment or other
             experimental protocols;

          -  Patient using unauthorized concomitant treatments including but not limited to
             baclofen, naltrexone, sorbitol (pharmaceutical form), opioids, levothyroxin and
             potentially neurotoxic drugs such as amiodarone, chloroquine, cancer drugs susceptible
             to induce a peripheral neuropathy. Patient who can/agrees to stop these medications 4
             weeks before randomization and during the whole study duration can be included;

          -  Female of childbearing potential (apart of patient using adequate contraceptive
             measures), pregnant or breast feeding;

          -  Known hypersensitivity to any of the individual components of PXT3003;

          -  Porphyria as it is a contra indication to baclofen, and it may also induce neuropathy;

          -  Suspected inability to complete the study follow-up (foreign workers, transient
             visitors, tourists or any others for whom follow-up evaluation is not assured);

          -  Limited mental capacity or psychiatric disease rendering the subject unable to provide
             written informed consent or comply with evaluation procedures;

          -  Patient who has participated in another trial of investigational drug(s) within the
             past 30 days;

          -  If a patient from the same family, living in the same household, has already been
             included in this study, it will not be possible to include another patient from the
             same family to avoid mixing of therapeutic units; therefore there would be a risk of
             inversion of the blind treatments which could jeopardize the interpretation of study
             results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahram Attarian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU La Timone, Marseille, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Young, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Munster, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Teresa Sevilla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari i Politécnic La Fe, Valencia, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marianne De Visser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philip Van Damme, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Roberts, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Salford Royal NHS Foundation Trust, Manchester, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Florian Thomas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint-Louis University, Saint-Louis, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neurology, Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Care, New Britain</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, McKnight Brain Institute</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology and Psichiatry, Saint Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104-1027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peripheral Neuropathy Center, Neurological Institue Building, Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Rehabilitation Institute</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202-1330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Departement of Neurology, UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Quebec</name>
      <address>
        <city>Quebec</city>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Référence des Maladies Neuromusculaires, Hôpital Swynghedauwl, CHU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Référence des Neuropathies Périphériques Rares, Hôpital Dupuytren, CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Neurologie et du Sommeil, CHU Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Référence des Maladies Neuromusculaires, Pôle des Neurosciences Clinique, CHU la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Référence des Maladies Neuromusculaires; Hôtel Dieu, CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Neurologie, Hôpital Kremlin Bicêtre</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology and Institute for Neuropathology, University Hospital RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Clinical Neurophysiology, University Medical Center Göttingen</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Ludwig-Maximillian University, Munich</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department for Sleep Medicine and Neuromuscular, University Hospital Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Departement of Neurology, Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of neurology, Hospital Univesitario de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicio de Neurologia, Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Diagnostico y Tratamiento, Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicio de Neurologia, Hospital Univesitari i Politécnic La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Salford</city>
        <state>Manchester</state>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ninewells Hospital and Medical School</name>
      <address>
        <city>Dundee</city>
        <state>Scotland</state>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Attarian S, Vallat JM, Magy L, Funalot B, Gonnaud PM, Lacour A, Péréon Y, Dubourg O, Pouget J, Micallef J, Franques J, Lefebvre MN, Ghorab K, Al-Moussawi M, Tiffreau V, Preudhomme M, Magot A, Leclair-Visonneau L, Stojkovic T, Bossi L, Lehert P, Gilbert W, Bertrand V, Mandel J, Milet A, Hajj R, Boudiaf L, Scart-Grès C, Nabirotchkin S, Guedj M, Chumakov I, Cohen D. An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A. Orphanet J Rare Dis. 2014 Dec 18;9:199. doi: 10.1186/s13023-014-0199-0. Erratum in: Orphanet J Rare Dis. 2016;11(1):92.</citation>
    <PMID>25519680</PMID>
  </results_reference>
  <results_reference>
    <citation>Chumakov I, Milet A, Cholet N, Primas G, Boucard A, Pereira Y, Graudens E, Mandel J, Laffaire J, Foucquier J, Glibert F, Bertrand V, Nave KA, Sereda MW, Vial E, Guedj M, Hajj R, Nabirotchkin S, Cohen D. Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy. Orphanet J Rare Dis. 2014 Dec 10;9:201. doi: 10.1186/s13023-014-0201-x.</citation>
    <PMID>25491744</PMID>
  </results_reference>
  <results_reference>
    <citation>Mandel J, Bertrand V, Lehert P, Attarian S, Magy L, Micallef J, Chumakov I, Scart-Grès C, Guedj M, Cohen D. A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment. Orphanet J Rare Dis. 2015 Jun 13;10:74. doi: 10.1186/s13023-015-0293-y.</citation>
    <PMID>26070802</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2015</study_first_submitted>
  <study_first_submitted_qc>October 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2015</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PXT3003</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tooth Diseases</mesh_term>
    <mesh_term>Charcot-Marie-Tooth Disease</mesh_term>
    <mesh_term>Nerve Compression Syndromes</mesh_term>
    <mesh_term>Hereditary Sensory and Motor Neuropathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

